Kodiak Sciences Inc.
A clinical-stage biotech developing next-generation medicines for retinal diseases that cause blindness, aiming for longer-lasting anti-VEGF eye injections with candidates like Zenkuda (tarcocimab tedromer) and the bispecific KSI-501. Founded in 2009 as Oligasis and renamed Kodiak Sciences in 2015, the company takes its name from Alaska's mighty Kodiak bear — and fittingly, its Swiss manufacturing plant is called "Ursus," the Latin word for bear.
Granted 150.0K · Bought 13.12M
Granted 300.0K · Sold 1.34M
Granted 122.7K · Sold 81.9K
Granted 122.2K · Sold 12.0K
Granted 291.7K · Sold 213.7K
Bought 10.0K
Bought 1.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 236 transactions | — | 19.92M | 150.0K | 13.12M | — |
| Perlroth VictorChairman and CEO, Director · 8 transactions | — | 2.40M | 300.0K | — | 1.34M |
| Borgeson John A.Chief Financial Officer · 34 transactions | — | 216.0K | 122.7K | — | 81.9K |
| Liang HongSVP, Discovery Medicine · 9 transactions | — | 130.2Kas of Apr 2020 | 122.2K | — | 12.0K |
| Ehrlich JasonSee Remarks · 163 transactions | — | 61.9Kas of Jun 2023 | 291.7K | — | 213.7K |
| Profusek RobertDirector · 1 transaction | — | 10.0Kas of Oct 2018 | — | 10.0K | — |
| Levy Richard SDirector · 2 transactions | — | 250as of Mar 2020 | — | 1.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +11.49M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.